chenodeoxycholic acid has been researched along with Cirrhosis in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 6 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ge, X; Guo, S; Jiao, T; Li, C; Liu, Y; Nan, F; Wang, K; Wang, Y; Xie, C; Xie, X; Yin, J; Zhang, C | 1 |
| Huang, X; Jiang, Z; Miao, Y; Tang, Q; Wang, J; Wu, Q; Xu, Y; Yu, Q; Yuan, Z; Zhang, H; Zhang, L; Zhang, Z | 1 |
| Hou, MC; Huang, CC; Huang, SF; Lee, TY; Li, TH; Lin, HC; Liu, SY; Yang, YY | 1 |
| Bowlus, C; Gao, L; Gershwin, ME; He, X; Leung, PSC; Wang, L; Woo, E; Yang, G | 1 |
| An, P; Huang, P; Jiang, LJ; Li, W; Li, Y; Lin, Y; Or, YS; Popov, YV; Qi, X; Vaid, KA; Wang, J; Wei, G; Zhang, S | 1 |
| Anstee, QM; Barritt, AS; Bonacci, M; Cawkwell, G; Harrison, S; Loomba, R; Nader, F; Noureddin, M; Ratziu, V; Rinella, M; Sanyal, AJ; Schattenberg, JM; Stepanova, M; Wong, B; Younossi, ZM | 1 |
| Bernuzzi, F; Carbone, M; Gershwin, ME; Invernizzi, P; Malinverno, F; Mousa, HS; Ronca, V | 1 |
| Adorini, L; D'Agati, V; Dobrinskikh, E; Dvornikov, A; Field, A; Garcia, G; Gonzalez, FJ; Gratton, E; Henriksen, K; Herman-Edelstein, M; Hill, A; Jiang, T; Kopp, JB; Krausz, KW; Levi, J; Levi, M; Lucia, S; Luo, Y; Myakala, K; Orlicky, D; Peng, Y; Pruzanski, M; Qiu, L; Ranjit, S; Rosenberg, AZ; Wang, D; Wang, XX; Xie, C | 1 |
| Da, J; He, Y; Liu, G; Wu, H; Xie, B | 1 |
| Jun, DW; Nguyen, MH; Oh, H; Saeed, WK | 1 |
| Duan, XP; Huo, XK; Liu, KX; Liu, ZH; Meng, Q; Peng, JY; Sun, HJ; Sun, PY; Wang, CY | 1 |
| Adorini, L; Cellai, I; Comeglio, P; Corcetto, F; Corno, C; Filippi, S; Maggi, M; Maneschi, E; Morelli, A; Pini, A; Sarchielli, E; Vannelli, GB; Vignozzi, L | 1 |
| Adorini, L; Gonzalez, FJ; Jiang, T; Levi, M; Lewis, L; Miyazaki-Anzai, S; Pruzanski, M; Scherzer, P; Shen, Y; Wang, XX | 1 |
| Baldelli, F; Cipriani, S; D'Amore, C; Distrutti, E; Fiorucci, S; Mencarelli, A; Palladino, G; Renga, B | 1 |
| Adorini, L; Carini, M; Cellai, I; Comeglio, P; Filippi, S; Gacci, M; Maggi, M; Maneschi, E; Morelli, A; Piccinni, MP; Saad, F; Sarchielli, E; Serni, S; Vannelli, GB; Vignozzi, L | 1 |
| Hu, Z; Liu, B; Ren, L; Song, G; Wang, C | 1 |
| Bogdarin, IuA; Vinnitskaia, OV | 1 |
| Dick, B; Frey, BM; Frey, FJ; Odermatt, A; Quattropani, C; Vogt, B | 1 |
3 review(s) available for chenodeoxycholic acid and Cirrhosis
| Article | Year |
|---|---|
Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends.
Topics: Animals; Bile Acids and Salts; Biomarkers; Chenodeoxycholic Acid; Combined Modality Therapy; Disease Management; Disease Progression; Disease Susceptibility; Fibrosis; Humans; Immunotherapy; Liver Cirrhosis, Biliary; Liver Transplantation; Molecular Targeted Therapy; Severity of Illness Index; Symptom Assessment; Treatment Outcome; Ursodeoxycholic Acid | 2020 |
From pathogenesis to novel therapies in the treatment of primary biliary cholangitis.
Topics: Autoimmunity; Bile Ducts, Intrahepatic; Chenodeoxycholic Acid; Cholangitis; Fibrosis; Humans; Immunotherapy; Liver; Liver Cirrhosis, Biliary; Molecular Targeted Therapy; Ursodeoxycholic Acid; Ustekinumab | 2017 |
Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment.
Topics: Biomarkers; Chenodeoxycholic Acid; Clinical Trials as Topic; Fatty Liver; Fibrosis; Humans; Liver; Magnetic Resonance Imaging; Non-alcoholic Fatty Liver Disease; Tomography, X-Ray Computed; Ultrasonography; Vitamin E | 2016 |
1 trial(s) available for chenodeoxycholic acid and Cirrhosis
| Article | Year |
|---|---|
Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis.
Topics: Adult; Aged; Chenodeoxycholic Acid; Double-Blind Method; Female; Fibrosis; Humans; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pruritus; Quality of Life | 2022 |
14 other study(ies) available for chenodeoxycholic acid and Cirrhosis
| Article | Year |
|---|---|
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
Topics: Animals; Betulinic Acid; Bile Acids and Salts; Ceramides; Fibrosis; Glucose; Inflammasomes; Inflammation; Islet Amyloid Polypeptide; Liver; Methionine; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Pentacyclic Triterpenes; Receptors, Cytoplasmic and Nuclear | 2022 |
Obeticholic acid aggravates liver injury by up-regulating the liver expression of osteopontin in obstructive cholestasis.
Topics: Alkaline Phosphatase; Animals; Chenodeoxycholic Acid; Cholestasis; Fibrosis; Hydroxyproline; Liver; Mice; Osteopontin | 2022 |
Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice.
Topics: Animals; Chenodeoxycholic Acid; Fibrosis; Heart Diseases; Interleukin-10; Mice; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear | 2022 |
A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction.
Topics: Animals; Chenodeoxycholic Acid; Fibrosis; Liver; Liver Cirrhosis; Mice; Mice, Inbred C57BL; Steroids | 2020 |
FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.
Topics: Albuminuria; Animals; Bile Acids and Salts; Chenodeoxycholic Acid; Cholesterol; Cholic Acids; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Endoplasmic Reticulum Stress; Fibrosis; Glomerular Mesangium; Humans; Kidney Tubules; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mitochondria; Obesity; Oxidative Stress; Podocytes; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled; RNA, Messenger; Signal Transduction; Triglycerides | 2018 |
Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR/Nrf2 signaling in db/db mice.
Topics: Animals; Chenodeoxycholic Acid; Diabetic Cardiomyopathies; Fibrosis; Lipid Metabolism; Male; Mice; Myocardium; NF-E2-Related Factor 2; Oxidative Stress; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Up-Regulation | 2019 |
Alisol B 23-acetate protects against non-alcoholic steatohepatitis in mice via farnesoid X receptor activation.
Topics: Animals; Chenodeoxycholic Acid; Cholestenones; Choline Deficiency; Dose-Response Relationship, Drug; Fibrosis; Gene Expression; Hepatocytes; Lipid Metabolism; Lipogenesis; Liver; Male; Methionine; Mice; Non-alcoholic Fatty Liver Disease; Pregnenediones; Primary Cell Culture; Protective Agents; Receptors, Cytoplasmic and Nuclear | 2017 |
Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis.
Topics: Airway Remodeling; Animals; Bleomycin; Chenodeoxycholic Acid; Collagen; Disease Models, Animal; Fibrosis; Gene Expression Profiling; Immunohistochemistry; Inflammation; Lung; Male; Pulmonary Alveoli; Pulmonary Fibrosis; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Ventricular Remodeling | 2017 |
The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria.
Topics: Animals; Chenodeoxycholic Acid; Diet; Extracellular Matrix Proteins; Fatty Acids; Fibrosis; Glomerular Mesangium; Inflammation Mediators; Intercellular Signaling Peptides and Proteins; Kidney; Kidney Glomerulus; Lipid Metabolism; Male; Mice; Mice, Inbred DBA; Mice, Knockout; Nephritis; Oxidative Stress; Podocytes; Proteinuria; Receptors, Cytoplasmic and Nuclear; Sterol Regulatory Element Binding Protein 1; Triglycerides | 2009 |
FXR activation improves myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity.
Topics: Acyl-CoA Oxidase; Animals; Apoptosis; Bile Acids and Salts; Blood Glucose; Cardiovascular Diseases; Chenodeoxycholic Acid; Dyslipidemias; Fibrosis; Hyperinsulinism; Hyperlipidemias; Insulin Resistance; Isoxazoles; Lipid Metabolism; Liver; Myocardium; Obesity; PPAR alpha; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Risk Factors; RNA, Messenger; Triglycerides | 2013 |
Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit.
Topics: Androgens; Animals; Biomarkers; Chenodeoxycholic Acid; Dietary Fats; Disease Models, Animal; Drug Evaluation, Preclinical; Estradiol; Fibrosis; Male; Metabolic Syndrome; Prostate; Prostatitis; Rabbits; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; RNA, Messenger; Testosterone | 2012 |
Effect of chenodeoxycholic acid on fibrosis, inflammation and oxidative stress in kidney in high-fructose-fed Wistar rats.
Topics: Animals; Biomarkers; Chenodeoxycholic Acid; Cytokines; Dietary Carbohydrates; Disease Models, Animal; Fibrosis; Fructose; Kidney; Lipid Metabolism; Male; Membrane Glycoproteins; NADPH Oxidase 2; NADPH Oxidases; Nephritis; Oxidative Stress; Plasminogen Activator Inhibitor 1; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Transforming Growth Factor beta1 | 2012 |
[The possibilities of the experimental lipid metabolism correction with chenodesoxycholic acid and galenic preparations].
Topics: Animals; Chenodeoxycholic Acid; Cholecystitis; Cholelithiasis; Female; Fibrosis; Gallbladder; Lipid Metabolism; Plant Extracts; Rabbits | 1996 |
Reduced activity of 11 beta-hydroxysteroid dehydrogenase in patients with cholestasis.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; 11-beta-Hydroxysteroid Dehydrogenases; Active Transport, Cell Nucleus; Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Bile Acids and Salts; Cell Line; Chenodeoxycholic Acid; Cholestasis; Dose-Response Relationship, Drug; Female; Fibrosis; Gas Chromatography-Mass Spectrometry; Humans; Hydrocortisone; Hydroxysteroid Dehydrogenases; Kidney; Male; Microscopy, Fluorescence; Middle Aged; Models, Chemical; Potassium; Sodium; Tetrahydrocortisol; Time Factors; Transfection | 2001 |